K2M Group Holdings, Inc.
Nov 1, 2017

K2M Group Holdings, Inc. Reports Third Quarter 2017 Financial Results

LEESBURG, Va., Nov. 01, 2017 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today reported financial results for its third fiscal quarter ended September 30, 2017. 

Third Quarter 2017 Financial Summary:

Third Quarter Product Introductions:

Recent Strategic Highlights:

"Our revenue results for the third quarter of 2017 reflect total revenue growth of 6% year-over-year on a GAAP basis and 5% on a constant currency basis," said Chairman, President and Chief Executive Officer, Eric Major. "Although we continued to see growth, our third quarter revenue performance was impacted by slower initial on-boarding of the new distribution team in the U.S., disruption of account activity and canceled procedures related to the hurricanes in Texas, Florida and Puerto Rico in early September.  Third quarter deformity trends were strong in July and August and we experienced strong headwinds in September. U.S. sales growth in our degenerative procedure category continued to be fueled by our new product introductions including our industry-leading 3D-printed portfolio, offset partially by modestly weaker procedure volumes as compared to last year."

Major continued, "We have made significant progress in 2017 toward our goal of introducing new and innovative spinal implant solutions. We have supplemented this organic growth activity with exciting strategic acquisitions of intellectual property for expandable implants and a cervical vertebral body replacement device that is the first and only static corpectomy cage in the world to receive a cervical 510(k) clearance. We also announced an important strategic collaboration with Brainlab, one of the world's leading imaging and navigation companies. We remain confident in our ability to drive above-market growth in the U.S., fueled by our continued focus on leading the spine market by introducing new and innovative spinal implant solutions to help surgeons care for patients around the world who suffer from debilitating spinal pathologies."

Third Quarter 2017 Financial Results

  Three Months Ended September 30, Increase / Decrease
  2017 2016 $ Change % Change % Change
($ in thousands)       (as reported) (constant currency)
United States $48,474  $45,978  $2,496  5.4% 5.4%
International 14,179  13,332  847  6.4% 5.2%
Total Revenue: $62,653  $59,310  $3,343  5.6% 5.4%

Total revenue for the third quarter of 2017 increased $3.3 million, or 5.6%, to $62.6 million, compared to $59.3 million for the third quarter of 2016. Total revenue increased 5.4% year-over-year on a constant currency basis. The increase in revenue was primarily driven by higher sales volume from new surgeon users in the United States, partially offset by a decrease in revenues from our existing U.S. and U.K. customer base and a reduction of revenue in Japan.

Revenue in the United States increased $2.5 million, or 5.4% year-over-year, to $48.5 million, and international revenue increased $0.8 million, or 6.4% year-over-year, to $14.2 million. Third quarter 2017 international revenue increased 5.2% year-over-year on a constant currency basis. Foreign currency exchange impacted third quarter international revenue by approximately $0.1 million, representing approximately 112 basis points of 2017 international growth year-over-year.

The following table represents domestic revenue by procedure category. 

  Three Months Ended September 30, Increase / Decrease
  2017 2016 $ Change % Change
($ in thousands)        
Complex Spine $20,047  $19,516  $531  2.7%
Minimally Invasive 7,694  6,767  927  13.7%
Degenerative and Other 20,733  19,695  1,038  5.3%
U.S Revenue: $48,474  $45,978  $2,496  5.4%

By procedure category, U.S. revenue in the Company's complex spine, MIS and degenerative categories represented 41.4%, 15.9% and 42.7% of U.S. revenue, respectively, for the three months ended September 30, 2017.

Gross profit for the third quarter of 2017 increased 6.1% to $42.2 million, compared to $39.8 million for the third quarter of 2016.  Gross margin was 67.4% for the third quarter of 2017, compared to 67.1% for the prior year period. Gross profit includes amortization expense on investments in surgical instruments of $3.5 million, or 5.5% of sales, for the three months ended September 30, 2017, compared to $3.5 million, or 5.8% of sales, for the comparable period last year.

Operating expenses for the third quarter of 2017 increased $3.7 million, or 8.0%, to $49.6 million, compared to $45.9 million for the third quarter of 2016. The increase in operating expenses was driven primarily by a $2.2 million increase in sales and marketing expenses, compared to the comparable period last year.

Loss from operations for the third quarter of 2017 increased $1.2 million to $7.3 million compared to a loss from operations of $6.1 million for the comparable period last year. Loss from operations included intangible amortization of $1.8 million and $2.6 million for the third quarters of 2017 and 2016, respectively. 

Total other expenses for the third quarter of 2017 decreased $0.8 million to $1.1 million, compared to $1.9 million last year. The decrease in other expense, net, was primarily attributable to an increase of $1.2 million in unrealized gains from foreign currency remeasurement on intercompany payable balances, partially offset by an increase in interest expense of $0.4 million from the Convertible Senior Notes issued in August 2016.   

Net loss for the third quarter of 2017 was $8.5 million, or $0.20 per diluted share, compared to a loss of $7.9 million, or $0.19 per diluted share, for the third quarter of 2016. 

Nine-Months 2017 Financial Results

  Nine Months Ended September 30, Increase / Decrease
  2017 2016 $ Change % Change % Change
($ in thousands)       (as reported) (constant currency)
United States $145,456  $133,409  $12,047  9.0% 9.0% 
International 44,774  41,434  3,340  8.1% 9.6% 
Total Revenue: $190,230  $174,843  $15,387  8.8% 9.2% 

For the nine months ended September 30, 2017, total revenue increased $15.4 million, or 8.8%, to $190.2 million, compared to $174.8 million for the nine months ended September 30, 2016. Total revenue increased 9.2% year-over-year on a constant currency basis. U.S. revenue increased $12.1 million, or 9.0%, to $145.5 million for the first nine months of 2017, compared to $133.4 million last year. International revenue increased $3.4 million, or 8.1%, to $44.8 million for the first nine months of 2017, compared to $41.4 million last year. International revenue increased 9.6% year-over-year on a constant currency basis.

  Nine Months Ended September 30, Increase / Decrease
($ in thousands) 2017 2016 $ Change % Change
Complex Spine $57,525  $53,981  $3,544  6.6%
Minimally Invasive 24,351  20,653  3,698  17.9%
Degenerative and Other 63,580  58,775  4,805  8.2%
U.S Revenue: $145,456  $133,409  $12,047  9.0%

Sales in our complex spine, MIS and degenerative categories represented 39.5%, 16.7% and 43.8% of U.S. revenue, respectively, for the first nine months of 2017.

As of September 30, 2017, we had cash and cash equivalents of $33.9 million as compared to $45.5 million as of December 31, 2016. We had working capital of $107.0 million as of September 30, 2017 as compared to $115.9 million as of December 31, 2016.

At September 30, 2017, outstanding long-term indebtedness included the carrying value of the Convertible Senior Notes of $38.6 million and the capital lease obligation of $34.1 million. The Company had no borrowings outstanding on its revolving credit facility as of September 30, 2017.

2017 Outlook

The Company is reaffirming its fiscal year 2017 revenue guidance expectations which were updated in a press release on October 8, 2017. The Company expects:

The Company is updating its fiscal year 2017 guidance expectations for net loss and adjusted EBITDA loss. The Company now expects:

Conference Call

Management will host a conference call at 5:00 p.m. Eastern Time on November 1st to discuss the results of the third quarter, and to host a question and answer session. Those who would like to participate may dial 844-579-6824 (734-385-2616 for international callers) and provide access code 99297954 approximately 10 minutes prior to the start of the call. A live webcast of the call will also be provided on the investor relations section of the Company's website at http://Investors.K2M.com/.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 99297954. The webcast will be archived on the investor relations section of the Company's website.

About K2M Group Holdings, Inc.

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company's technologies, techniques and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects.  In some cases, you can identify these forward-looking statements by the use of words such as, "outlook," "guidance," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words.  Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products and retain their use of our products; pricing pressures and our ability to compete effectively generally in our industry; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payors; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in the industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions to our corporate headquarters and operations facilities or critical information technology systems, distributors or surgeon users; our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible  senior notes and our credit facility;  continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock price; our lack of current plans to pay cash dividends; our ability to take advantage of certain reduced disclosure requirements and exemptions as a result of being an emerging growth company; increased costs and additional regulations and requirements as a result of no longer qualifying as an emerging growth company as of December 31, 2017; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K filed with the SEC and our Quarterly Report filed with the SEC on August 2, 2017, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC.

We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release.  We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made.  We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.  We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.

(In Thousands, Except Share and Per Share Data)
  September 30, December 31,
  2017 2016
Current assets:    
Cash and cash equivalents $33,941   $45,511  
Accounts receivable, net 45,032   46,430  
Inventory, net 72,389   61,897  
Prepaid expenses and other current assets 7,516   6,147  
Total current assets 158,878   159,985  
Property, plant and equipment, net 49,927   50,714  
Goodwill 121,814   121,814  
Intangible assets, net 17,247   22,758  
Other assets, net 30,729   28,254  
Total assets $378,595   $383,525  
Current liabilities:    
Current maturities under capital lease obligation $1,083   $973  
Accounts payable 22,316   15,367  
Accrued expenses 18,505   15,673  
Accrued payroll liabilities 9,990
Total current liabilities 51,894   44,081  
Convertible senior notes
 38,584   36,894  
Capital lease obligation, net of current maturities 34,104   34,933  
Deferred income taxes, net 5,017   5,017  
Other liabilities 301   1,032  
Total liabilities 129,900   121,957  
Stockholders' equity:    
Common stock, $0.001 par value, 750,000,000 shares authorized; 43,343,567 and 42,291,352 shares issued and 43,327,602 and 42,282,741shares outstanding, respectively 43   42  
Additional paid-in capital 487,791   474,512  
Accumulated deficit (239,478)  (211,081) 
Accumulated other comprehensive loss 650   (1,771) 
Treasury stock, at cost, 15,965 and 8,611 shares, respectively (311)  (134) 
Total stockholders' equity 248,695   261,568  
Total liabilities and stockholders' equity $378,595   $383,525  

(In Thousands, Except Share and Per Share Data)
  Three Months Ended September 30, Nine Months Ended September 30,
  2017 2016 2017 2016
Revenue $62,653   $59,310   $190,230   $174,843  
Cost of revenue 20,425   19,512   64,426   58,747  
Gross profit 42,228   39,798   125,804   116,096  
Operating expenses:        
Research and development 5,360   5,199   16,170   15,989  
Sales and marketing 29,557   27,384   91,273   84,132  
General and administrative 14,659   13,312   42,937   41,343  
Total operating expenses 49,576   45,895   150,380   141,464  
Loss from operations (7,348)  (6,097)  (24,576)  (25,368) 
Other expense, net:        
Foreign currency transaction gain (loss) 671   (547)  1,518   (1,099) 
Interest expense (1,748)  (1,319)  (5,211)  (2,705) 
Total other expense, net (1,077)  (1,866)  (3,693)  (3,804) 
Loss before income taxes (8,425)  (7,963)  (28,269)  (29,172) 
Income tax expense (benefit) 40   (53)  128   21  
Net loss $(8,465)  $(7,910)  $(28,397)  $(29,193) 
Basic and diluted $(0.20)  $(0.19)  $(0.67)  $(0.70) 
Weighted average shares outstanding:        
Basic and diluted 43,009,015   41,940,370   42,627,985   41,639,609  

(In Thousands)
  Nine Months Ended September 30, 
  2017  2016
Operating activities     
Net loss $(28,397)  $(29,193)  
Adjustments to reconcile net loss to net cash used in operating activities:     
Depreciation and amortization 21,424    21,452   
Provision for inventory reserves 3,187    2,817   
Provision for allowance for doubtful accounts 196    (18)  
Stock-based compensation expense 4,322    5,381   
Accretion of discounts and amortization of issuance costs of convertible senior notes 1,748    558   
Other (14)   (33)  
Changes in operating assets and liabilities:     
Accounts receivable 2,444    (5,292)  
Inventory (9,510)   (6,466)  
Prepaid expenses and other assets (8,200)   (7,636)  
Accounts payable, accrued expenses, and accrued payroll liabilities 4,092    3,442   
Net cash used in operating activities (8,708)   (14,988)  
Investing activities     
Purchase of surgical instruments (7,199)   (10,986)  
Purchase of property, plant and equipment (3,242)   (16,338)  
Changes in cash restricted for leasehold improvements -    6,153   
Purchase of intangible assets (1,050)   (1,282)  
Net cash used in investing activities (11,491)   (22,453)  
Financing activities     
Borrowings on bank line of credit     19,500   
Payments on bank line of credit     (19,500)  
Proceeds from issuance of convertible senior notes, net of issuance costs     47,575   
Principal payments under capital lease (719)      
Issuances and exercise of stock-based compensation benefit plans, net of income tax 8,781    1,262   
Net cash provided by financing activities 8,062    48,837   
Effect of exchange rate changes on cash and cash equivalents 567    75   
Net change in cash and cash equivalents (11,570)   11,471   
Cash and cash equivalents at beginning of period 45,511    34,646   
Cash and cash equivalents at end of period $33,941   $46,117   
Significant non-cash investing activities     
Leasehold improvements under capital lease $   $598   
Additions to property, plant and equipment $250   $   
Significant non-cash financing activities     
Deferred convertible senior notes issuance costs $   $ 486   
Cash paid for:     
Income taxes $132   $177   
Interest $2,190   $339   

Reconciliation of GAAP to Non-GAAP Measures
 (In Thousands)

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of revenue in constant currency, Adjusted Gross Profit, and Adjusted EBITDA.

The Company presents these non-GAAP measures because it believes these measures are useful indicators of the Company's operating performance.  Management uses these non-GAAP measures principally as a measure of the Company's operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate companies in the Company's industry.  The Company also believes that these measures are useful to its management and investors as a measure of comparative operating performance from period to period.

Constant currency information compares results between periods as if exchange rates had remained constant period-to-period.  We calculate constant currency by converting the prior-year results using current-year foreign currency exchange rates.

Adjusted Gross Profit represents Gross Profit less amortization expense of surgical instruments.  The Company presented Adjusted Gross Profit because it believes it is a useful measure of the Company's gross profit and operating performance because the measure is not burdened by the timing impact of instrument purchases and related amortization. 

Adjusted EBITDA represents net loss plus interest expense, income tax expense, depreciation and amortization, stock-based compensation expense and foreign currency transaction (gain) loss.

The Company presents Adjusted EBITDA because it believes it is a useful indicator of the Company's operating performance.  Management uses Adjusted EBITDA principally as a measure of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. 

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to net loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP and it should not be construed as an inference that the Company's future results will be unaffected by unusual or non-recurring items.  In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future.  Adjusted EBITDA contains certain other limitations, including the failure to reflect the Company's cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized.  In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation.  The Company's presentation of Adjusted EBITDA should not be construed to imply that the Company's future results will be unaffected by any such adjustments.  Management compensates for these limitations by primarily relying on its GAAP results in addition to using Adjusted EBITDA supplementally.  The Company's definition of Adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

The following table presents reconciliations of gross profit to adjusted gross profit and net loss to Adjusted EBITDA for the periods presented.

  Three Months Ended September 30, Nine Months Ended September 30, 
  2017 2016 2017
Reconciliation from Gross Profit to Adjusted Gross Profit         
Gross profit $42,228  $39,798  $125,804  $116,096 
Surgical instrument amortization 3,456  3,454  10,525  10,150 
Adjusted gross profit (a Non-GAAP Measure) $45,684  $43,252  $136,329  $126,246 

  Three Months Ended September 30, Nine Months Ended September 30,
  2017 2016
 2017 2016
Reconciliations from Net Loss to Adjusted EBITDA  
Net loss $(8,465)  $(7,910)  $(28,397)  $(29,193)  
Interest expense 1,748   1,319   5,211   2,705   
Income tax expense 40   (53)  128   21   
Depreciation and amortization 6,810   7,415   21,424   21,452   
Stock-based compensation expense 1,442   1,527   4,322   5,381   
Foreign currency transaction (gain) loss (671)  547   (1,518)  1,099   
Adjusted EBITDA (a Non-GAAP Measure) $904   $2,845   $1,170   $1,465   

The following table presents a reconciliation of net loss to Adjusted EBITDA for our 2017 guidance:

  Year Ended
December 31,
Net loss $(36,000) 
Interest expense 6,900  
Income tax expense 200  
Depreciation and amortization 26,900  
Stock-based compensation expense 6,000  
Foreign currency transaction gain (2,000) 
Adjusted EBITDA $2,000  

The reconciliation assumes the mid-point of the Adjusted EBITDA range and the mid-point of each component of the reconciliation, corresponding to guidance of $1.0 million to $3.0 million for 2017. 

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA